{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T01:29:00Z","timestamp":1777598940242,"version":"3.51.4"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychoneuroendocrinology"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.psyneuen.2016.01.022","type":"journal-article","created":{"date-parts":[[2016,1,23]],"date-time":"2016-01-23T12:15:37Z","timestamp":1453551337000},"page":"214-220","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Altered metabolic parameters in association with antipsychotic medication use in diabetes: A population based case-control study"],"prefix":"10.1016","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6963-1335","authenticated-orcid":false,"given":"D.J.","family":"Wake","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Broughton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.M.","family":"Perera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.J.","family":"MacIntyre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.P.","family":"Leese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.psyneuen.2016.01.022_bib0005","first-page":"135","article-title":"Use of the second-generation antipsychotic, risperidone, and secondary weight gain are associated with an altered gut microbiota in children","volume":"6","author":"Bahr","year":"2015","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.psyneuen.2016.01.022_bib0010","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/bdi.12160","article-title":"Metabolic syndrome in bipolar disorder and schizophrenia: dietary and lifestyle factors compared to the general population","volume":"16","author":"Bly","year":"2014","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.psyneuen.2016.01.022_bib0015","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1192\/bjp.184.47.s87","article-title":"Association between atypical antipsychotic agents and type 2 diabetes: review of prospective clinical data","volume":"47","author":"Bushe","year":"2004","journal-title":"Br. J. Psychiatry Suppl."},{"key":"10.1016\/j.psyneuen.2016.01.022_bib0020","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1111\/j.1742-1241.2009.02224.x","article-title":"Changes in weight and metabolic parameters during treatment with antipsychotics and metformin: do the data inform as to potential guideline development? A systematic review of clinical studies","volume":"63","author":"Bushe","year":"2009","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.psyneuen.2016.01.022_bib0025","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/j.2051-5545.2009.tb00199.x","article-title":"Metabolic syndrome in people with schizophrenia: a review","volume":"8","author":"De Hert","year":"2009","journal-title":"World Psychiatry"},{"key":"10.1016\/j.psyneuen.2016.01.022_bib0030","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1192\/bjp.184.47.s72","article-title":"Stress and the genesis of diabetes mellitus in schizophrenia","volume":"47","author":"Dinan","year":"2004","journal-title":"Br. J. Psychiatry Suppl."},{"key":"10.1016\/j.psyneuen.2016.01.022_bib0035","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1345\/aph.1M550","article-title":"Efficacy of metformin and topiramate in prevention and treatment of second-generation antipsychotic-induced weight gain","volume":"44","author":"Ellinger","year":"2010","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.psyneuen.2016.01.022_bib0040","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1192\/bjp.bp.108.052605","article-title":"Metabolic profile of antipsychotic-naive individuals with non-affective psychosis","volume":"194","author":"Fernandez-Egea","year":"2009","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.psyneuen.2016.01.022_bib0045","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1192\/bjp.184.47.s80","article-title":"Antipsychotics and diabetes: review of non-prospective data","volume":"47","author":"Haddad","year":"2004","journal-title":"Br. J. Psychiatry Suppl."},{"key":"10.1016\/j.psyneuen.2016.01.022_bib0050","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1177\/0269881105058379","article-title":"Diabetes and schizophrenia 2005: are we any closer to understanding the link?","volume":"19","author":"Holt","year":"2005","journal-title":"J. Psychopharmacol. Oxf. Engl."},{"key":"10.1016\/j.psyneuen.2016.01.022_bib0055","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1471-4159.2011.07590.x","article-title":"Structural contributions of antipsychotic drugs to their therapeutic profiles and metabolic side effects","volume":"120","author":"Jafari","year":"2012","journal-title":"J. Neurochem."},{"key":"10.1016\/j.psyneuen.2016.01.022_bib0060","series-title":"British National Formulary 68","author":"Joint Formulary Committee","year":"2014"},{"key":"10.1016\/j.psyneuen.2016.01.022_bib0065","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/schbul\/sbq058","article-title":"Is abnormal glucose tolerance in antipsychotic-naive patients with nonaffective psychosis confounded by poor health habits?","volume":"38","author":"Kirkpatrick","year":"2012","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.psyneuen.2016.01.022_bib0070","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.2337\/dc07-0553","article-title":"Scottish foot ulcer risk score predicts foot ulcer healing in a regional specialist foot clinic","volume":"30","author":"Leese","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.psyneuen.2016.01.022_bib0075","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/j.1368-5031.2006.00899.x","article-title":"Stratification of foot ulcer risk in patients with diabetes: a population-based study","volume":"60","author":"Leese","year":"2006","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.psyneuen.2016.01.022_bib0080","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.schres.2010.08.022","article-title":"Rethinking the genetic basis for comorbidity of schizophrenia and type 2 diabetes","volume":"123","author":"Lin","year":"2010","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.psyneuen.2016.01.022_bib0085","doi-asserted-by":"crossref","first-page":"701","DOI":"10.2165\/00003495-200464070-00003","article-title":"Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications","volume":"64","author":"Melkersson","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.psyneuen.2016.01.022_bib0090","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1192\/bjp.bp.111.094532","article-title":"Differences in the prescribing of medication for physical disorders in individuals with v: without mental illness: meta-analysis","volume":"201","author":"Mitchell","year":"2012","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.psyneuen.2016.01.022_bib0095","first-page":"9","article-title":"The antipsychotic olanzapine interacts with the gut microbiome to cause weight gain in mouse","author":"Morgan","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.psyneuen.2016.01.022_bib0100","unstructured":"NHS Diabetes, 2011. Commissioning Mental Health and Diabetes Service."},{"key":"10.1016\/j.psyneuen.2016.01.022_bib0105","unstructured":"NICE, 2014. CG178 Psychosis and schizophrenia in adults: full guideline."},{"key":"10.1016\/j.psyneuen.2016.01.022_bib0110","first-page":"276","article-title":"Metabolic changes in first-episode early-onset schizophrenia with second-generation antipsychotics. Early Interv","volume":"8","author":"O\u2019Donoghue","year":"2014","journal-title":"Psychiatry"},{"key":"10.1016\/j.psyneuen.2016.01.022_bib0115","unstructured":"Perera, S., Cochrane, L., Wang, Y., MacIntyre, D., Wake, D., 2013. Diabetes and Schizophrenia: Exploring Associations. (Manchester)."},{"key":"10.1016\/j.psyneuen.2016.01.022_bib0120","first-page":"198","article-title":"Lipid profile in antipsychotic drug users: a comparative study","volume":"9","author":"Roohafza","year":"2013","journal-title":"ARYA Atheroscler."},{"issue":"Suppl. 4","key":"10.1016\/j.psyneuen.2016.01.022_bib0125","doi-asserted-by":"crossref","first-page":"S345","DOI":"10.1016\/S0924-9338(05)80189-0","article-title":"Schizophrenia and diabetes: epidemiological data","volume":"20","author":"Rouillon","year":"2005","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.psyneuen.2016.01.022_bib0130","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.schres.2010.07.012","article-title":"Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis","volume":"123","author":"Rummel-Kluge","year":"2010","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.psyneuen.2016.01.022_bib0135","unstructured":"Scottish Intercollegiate Guidelines Network (SIGN), 2013. SIGN 131: Management of schizophrenia (Edinburgh)."},{"key":"10.1016\/j.psyneuen.2016.01.022_bib0140","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1192\/bjp.bp.107.037184","article-title":"First-v: second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis","volume":"192","author":"Smith","year":"2008","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.psyneuen.2016.01.022_bib0145","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/YIC.0000000000000014","article-title":"Pharmacological treatment of antipsychotic-induced dyslipidemia and hypertension","volume":"29","author":"Tse","year":"2014","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.psyneuen.2016.01.022_bib0150","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1177\/104012371302500209","article-title":"An exploratory study examining lipid-lowering medications in reducing fasting serum lipids in schizophrenia patients treated with atypical antipsychotics","volume":"25","author":"Vincenzi","year":"2013","journal-title":"Ann. Clin. Psychiatry"},{"key":"10.1016\/j.psyneuen.2016.01.022_bib0155","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1111\/j.1464-5491.2007.02324.x","article-title":"Quality of diabetes care in patients with schizophrenia and bipolar disorder: cross-sectional study","volume":"24","author":"Whyte","year":"2007","journal-title":"Diabet. Med."}],"container-title":["Psychoneuroendocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306453016300208?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306453016300208?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T16:52:46Z","timestamp":1759683166000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306453016300208"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":31,"alternative-id":["S0306453016300208"],"URL":"https:\/\/doi.org\/10.1016\/j.psyneuen.2016.01.022","relation":{},"ISSN":["0306-4530"],"issn-type":[{"value":"0306-4530","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Altered metabolic parameters in association with antipsychotic medication use in diabetes: A population based case-control study","name":"articletitle","label":"Article Title"},{"value":"Psychoneuroendocrinology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psyneuen.2016.01.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}